Small molecule glp-1 agonists

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof;
• wherein,
• A is optionally substituted arylene, heteroarylene, or heterocycloalkylene;
• B is -(alkylene)O(alkylene)-, alkylene, haloalkylene, alkenylene, —O(alkylene)-, -(alkylene)O—, —O(alkylene)O—, —O(alkylene)O(alkylene)-, -(alkylene)O(alkylene)O—, —S(alkylene)-, -(alkylene)S—, -(alkylene)S(alkylene)-, —S(alkylene)S—, —S(alkylene)S(alkylene)-, -(alkylene)S(alkylene)S—, —NH(alkylene)-, -(alkylene)NH—, -(alkylene)NH(alkylene)-, —NH(alkylene)NH—, —NH(alkylene)NH(alkylene)-, -(alkylene)NH(alkylene)NH—, —N(alkyl)(alkylene)-, -(alkylene)N(alkyl)-, or is a bond;
• C is optionally substituted arylene, heteroarylene, or heterocycloalkylene;
• Ring D is
• Ring Z is heterocycloalkylene or heteroarylene;
• R1 is independently for each occurrence alkyl, alkoxy, or halo;
• or two geminal occurrences of R1 taken together with the carbon atom to which they are attached form an optionally substituted spirocyclic cycloalkyl ring;
• R2 is independently for each occurrence alkyl, alkoxy, or halo;
• R3 is haloalkyl, unsubstituted cycloalkyl, cycloalkyl substituted with alkyl, cycloalkyl substituted with haloalkyl, cycloalkyl substituted with halo, unsubstituted heteroaryl, heteroaryl substituted with alkyl, heteroaryl substituted with halo, unsubstituted heterocycloalkyl, heterocycloalkyl substituted with alkyl, heterocycloalkyl substituted with halo, haloalkoxy, —NH2, —NH(alkyl), or —N(alkyl)2;
• R3a is independently for each occurrence alkyl, alkoxy, halo, haloalkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, haloalkoxy, —NH2, —NH(alkyl), or —N(alkyl)2;
• R4 is independently for each occurrence alkyl, alkoxy, or halo;
• k is an integer selected from 0-2;
• m is an integer selected from 0-6;
• n is an integer selected from 0-4;
• p is an integer selected from 0-4;
• and
• q is an integer selected from 0-2.